ClinicalTrials.gg
Biological

Human Papillomavirus Recombinant Vaccine nonavalent clinical trials

Its developmentBy 5 companies, company by company25 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.
studies test it
74
open now
20
in phase 3
31
first study started
2009

How each study uses Human Papillomavirus Recombinant Vaccine nonavalent is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Human Papillomavirus Recombinant Vaccine nonavalent studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
10 Dec 2014 · Gardasil 9 · BLA 125508 (FDA, Purple Book)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Gardasil9
19
V503
17
Gardasil 9
15
9vHPV vaccine
14
9-valent HPV vaccine
11

Studies by the year they started

74 studies that test it; most in 2022 (10)

Studies that test Human Papillomavirus Recombinant Vaccine nonavalent, by start year
YearStudies
20091
20101
20112
20121
20131
20142
20163
20177
20184
20196
20208
20216
202210
20233
20246
20257
20266

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
1
Phase 2
13
Phase 3
31
Phase 4
28
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 23 · Other 51

Merck Sharp & Dohme LLC (20) · National Cancer Institute (NCI) (5) · Indiana University (2) · Boston Medical Center (2) · London School of Hygiene and Tropical Medicine (2) · Emory University (2) · Fred Hutchinson Cancer Center (2) · Shanghai Bovax Biotechnology Co., Ltd. (2)

Often tested with

Tested in the same studies.

Human papillomavirus vaccine, L1 type 16, 18 (4) · Meningococcal Vaccines (1) · Diphtheria-Tetanus-acellular Pertussis Vaccines (1) · Lidocaine (1) · 2019-nCoV Vaccine mRNA-1273 (1) · Papillomavirus Vaccines (1) · Imiquimod (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Human Papillomavirus Recombinant Vaccine nonavalent is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 8, 1 in phase 3

Studies that test Human Papillomavirus Recombinant Vaccine nonavalent, phase 3 first.

Studies

Open first, then newest update. How each study uses Human Papillomavirus Recombinant Vaccine nonavalent is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 74

See all 74 studies that test Human Papillomavirus Recombinant Vaccine nonavalent →

Given beside what is tested · 5 — Human Papillomavirus Recombinant Vaccine nonavalent is usual care or a partner of the new treatment
As the comparator · 10 — what is tested is compared with Human Papillomavirus Recombinant Vaccine nonavalent